This 60-minute didactic and case-based session addresses evolving evidence and treatment approaches for Duchenne Muscular Dystrophy (DMD), including:

• Latest clinical trial data
• Assess the latest data from clinical studies with DMD treatments to help inform clinical decision making
• Aligning treatment strategies to individual patient needs

Available from now until the end of March 2026

A 60-minute didactic and case-based session aimed covering:

• DMD Overview: Pathophysiology, prevalence, diagnostic challenges, and the multi-system burden on patients
• Monitoring Corticosteroid Side Effects: Importance of proactive, interdisciplinary care to manage avoidable morbidity
• Comparing Corticosteroid Options: Efficacy, safety, and long-term data from clinical trials and observational studies, including the SUMMIT study
• Corticosteroids in the Gene Therapy Era: Real-world case examples highlighting polypharmacy, therapy sequencing, and patient outcomes

Available from now until the end of March 2026

A 60-minute didactic and case-based session aimed covering:

• The pathophysiology of DMD, specifically in relation to muscle degeneration, chronic inflammation, adipogenesis, and fibrogenesis
• Discuss new and novel DMD treatment approaches, to help determine safety, and patient selection to optimize their efficacy

Available from January 2026 until the end of June 2026

A 60-minute aimed at increasing neurologists’ awareness and knowledge of Factor XI/XIa (FXI/FXIa) inhibition, covering:

• The role of Factor XI in thrombosis versus hemostasis and its implications for stroke prevention
• Recent clinical trial data (PACIFIC-STROKE, AXIOMATIC SSP, and ongoing phase 3 programs) to determine potential practice implications of FXIa inhibitors in secondary stroke prevention
• Clinical scenarios to identify how FXIa inhibitors may address residual stroke risk while minimizing bleeding concern

Available from April 2026 until the end of March 2027